Modular particles for immunotherapy

Patent metadata

Field	Value
Publication number	US-9884026-B2
Application number	US-201415034106-A
Country	US
Kind code	B2
Filing date	Oct 31, 2014
Priority date	Nov 1, 2013
Publication date	Feb 6, 2018
Grant date	Feb 6, 2018

Abstract

Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.

First claim

I claim:

1. A nanoparticulate composition comprising
a) a delivery vehicle selected from the group consisting of: a nanolipogel comprising a polymeric core and a lipid shell; and a biodegradable particle; and
b) IL- 2 and losartan loaded into, attached to the surface of, and/or enclosed within the delivery vehicle.

2. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a nanolipogel comprising a polymeric core formed of non-crosslinkable polymers.

3. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a nanolipogel comprising a polymeric core formed of one or more crosslinkable polymers.

4. The nanoparticulate composition of claim 3 , wherein the polymers in the polymeric core are cross-linked by way of one or more photo-polymerizable groups.

5. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a nanolipogel comprising a polymeric core formed of a block copolymer containing one or more poly(alkylene oxide) segments selected from polyethylene glycol, polypropylene, 1,2-glycol, poly(propylene oxide) and/or polypropylene 1,3-glycol segments; and/or one or more aliphatic polyester segments selected from polylactic acid (PLA), polyglycolic acid (PGA), and/or polylactide-coglycolide (PLGA) segments.

6. The nanoparticulate composition of claim 5 , wherein the polymeric core further comprises one or more photo-polymerisable groups.

7. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a nanolipogel comprising a polymer matrix core containing one or more host molecules dispersed within or covalently bound to the polymeric matrix, and a lipid shell.

8. The nanoparticulate composition of claim 7 , wherein the host molecule is selected from the group consisting of polysaccharides, cyclodextrins, cryptands, cryptophanes, cavitands, crown ethers, dendrimers, catenanes, polycatenanes, carcerands, spherands, carbon nanotubes, fullerenes, inorganic phosphates, and silica.

9. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a nanolipogel comprising a polymeric core containing one or more host molecules and a lipid shell; and wherein each of the IL-2 and losartan is dispersed within the polymeric core, dispersed within the lipid shell, and/or attached to the lipid shell.

10. The nanoparticulate composition of claim 9 , wherein the losartan is associated with a host molecule and the IL-2 is dispersed within the polymeric core.

11. The nanoparticulate composition of claim 1 , wherein the delivery vehicle is a polymeric nanoparticle formed of one or more polymers selected from polymers of hyroxyacids, and copolymers of the hydoxyacids with polyethylene glycol, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), and blends and copolymers thereof.

12. The nanoparticulate composition of claim 1 , further comprising one or more active agents loaded into, attached to the surface of, and/or enclosed within said delivery vehicle, wherein the delivery vehicle is decorated with a target moiety selected from the group consisting of RGD peptide, a CD40 agonist, an anti-CD40 antibody or fragment thereof, a T cell receptor (TCR), an IL-15/IL-15Rα complex, and a moiety that targets antigen presenting cells.

13. The nanoparticulate composition of claim 12 , wherein the TCR is a T cell receptor that recognizes the p53 antigen.

14. The nanoparticulate composition of claim 1 , further comprising at least one additional active agent which is an immune modulator or a chemotherapeutic agent, wherein the at least one additional active agent is not loaded into, attached to the surface of or enclosed within said delivery vehicle.

15. The nanoparticulate composition of claim 14 , wherein the immune modulator is an immune response stimulating agent; an agent that blocks immune suppression; or an agent that targets tumor checkpoint blockade or costimulatory molecules.

16. The nanoparticulate composition of claim 15 , wherein the immune response stimulating agent is a PD-1 antagonist, a CTLA4 antagonist or a combination thereof.

17. A method of increasing or improving an immune stimulating or immune enhancing effect of an immune response stimulating agent or a chemotherapeutic agent comprising administering to a subject in need thereof an effective amount of composition of claim 1 in combination with an immune response stimulating agent or chemotherapeutic agent to increase an immune stimulating or immune enhancing effect of the immune response stimulating agent or the chemotherapeutic agent.

18. The method of claim 17 , wherein the composition and the immune response stimulating agent or the chemotherapeutic agent are administered separately and independently to the subject, at the same time or at different times.

19. The method of claim 17 , wherein the immune response stimulating agent is a PD-1 antagonist, or a CTLA4-antagonist.

20. The method of claim 17 , wherein the chemotherapeutic agent is doxorubicin.

21. A method of treating cancer comprising administering to a subject with cancer an effective amount of composition of claim 1 to reduce one or more symptoms of the cancer.

Assignees

• Univ Yale

Inventors

• Fahmy Tarek
• Horsburgh Brian

Classifications

• A61K38/208

  IL-12 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/2086

  IL-13 to IL-16 · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• A61K9/5146

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title